HRCT and Pulmonary Function Test Surveillance for NSIP on Biologic Therapy

Surveillance Schedule

A decline of ≥5% absolute or ≥10% relative in FVC over 6 months indicates significant progression and warrants immediate reassessment, according to the European Respiratory Society 1
A decrease of ≥15% in DLCO over 6 months is similarly concerning for progression, as reported by the European Respiratory Review 1
These functional changes should trigger earlier HRCT imaging regardless of scheduled timing, as recommended by Radiologia Medica 2
Obtain baseline HRCT at diagnosis using volumetric acquisition with thin sections (≤1.5 mm) at full inspiration, as suggested by Radiologia Medica 2
Follow-up HRCT should be performed within 12 months of the previous scan for patients with stable clinical and functional status, according to Radiologia Medica 2

NSIP characteristically shows bilateral ground-glass opacities as the predominant finding, as described by the American Thoracic Society 3
Irregular reticular opacities with traction bronchiectasis occur in approximately 75% of cases, as reported by the American Journal of Respiratory and Critical Care Medicine 3
Subpleural sparing helps distinguish NSIP from usual interstitial pneumonia (UIP) pattern, as noted by the American Journal of Respiratory and Critical Care Medicine 3

Assess dyspnea severity at each visit as worsening breathlessness correlates with disease progression, according to the European Respiratory Review 1
Monitor oxygen saturation during 6-minute walk test, with SpO2 ≤88% indicating severe disease, as recommended by the European Respiratory Review 1
New or worsening symptoms should prompt immediate PFT and consideration of earlier HRCT, as suggested by Autoimmunity Reviews and Radiologia Medica 4, 2
HRCT interpretation must incorporate clinical context, prior imaging, and functional data, as emphasized by Radiologia Medica 2

Inadequate image quality necessitates repeat HRCT if technical requirements are not met, as recommended by Radiologia Medica 2
Do not wait for scheduled 12-month HRCT if clinical or functional decline occurs, as advised by Radiologia Medica 2
Delayed recognition of progressive fibrosis may miss the window for treatment escalation, as warned by Autoimmunity Reviews 4

Significant functional decline (FVC drop ≥10% or DLCO drop ≥15%) indicates need for treatment modification, according to the European Respiratory Review 1

The American College of Rheumatology recommends mycophenolate as the preferred first-line therapy for NSIP pattern ILD, regardless of underlying cause, due to its favorable efficacy and safety profile 5, 6
Typical dosing of mycophenolate is 1000-1500 mg twice daily, with monitoring of complete blood count with differential every 2-4 months 7
Rituximab is a conditionally recommended alternative for NSIP pattern ILD, particularly when elevated IgE suggests an autoimmune component 5, 8

For patients with predominant fibrotic features, the American Thoracic Society suggests considering adding nintedanib to immunosuppressive therapy 5, 8
In cases of progressive disease despite first-line therapy, the European Respiratory Society recommends considering switching to or adding rituximab, cyclophosphamide, or nintedanib 5, 9

The American Thoracic Society recommends pulmonary function tests (PFTs) including forced vital capacity (FVC) and diffusing capacity (DLCO) every 3-6 months 10
High-resolution CT scan is recommended at baseline and as clinically indicated (typically annually or with significant PFT changes) 11

The American College of Rheumatology advises against overreliance on glucocorticoids for long-term management due to the risk of adverse effects 5, 9
Delayed initiation of second-line therapy in progressive disease is discouraged by the American College of Rheumatology 8, 6